AB 2760 (Wood, Chapter 324) was signed into law in 2018 and becomes effective on January 1, 2019. This bill requires prescribers to offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when certain conditions, which are specified in the bill, are present. This bill also requires a prescriber, consistent with the existing standard of care, to provide education to a patient and his or her designee, or if the patient is a minor, to the patient’s parent or guardian, on overdose prevention and the use of naloxone or other similar drug approved by the FDA.

For additional information, please review the Board’s FAQs and the language in AB 2760.

If you have further questions on AB 2760, please contact Jennifer Simoes, the Board’s Chief of Legislation,